Analysis of KIT expression and KIT exon 11 mutations in canine oral malignant melanomas

Veterinary and Comparative Oncology

Volumn 9, Issue 3, 2011, Pages 219-224

  Murakami, A ^a   Mori, T ^a   Sakai, H ^a   Murakami, M ^a   Yanai, T ^a   Hoshino, Y ^a   Maruo, K ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

KIT; Oral melanoma; Prognosis; Targeted therapy

Indexed keywords

STEM CELL FACTOR RECEPTOR;

ANIMAL; ANIMAL DISEASE; ARTICLE; DOG; DOG DISEASE; EXON; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; MELANOMA; METABOLISM; MOUTH TUMOR; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION;

ANIMALS; DNA MUTATIONAL ANALYSIS; DOG DISEASES; DOGS; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; MELANOMA; MOUTH NEOPLASMS; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-KIT;

CANIS FAMILIARIS;

EID: 80051785621     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2010.00253.x     Document Type: Article

References (30)

1. Modiano JF, Ritt MG and Wojcieszyn J. The molecular basis of canine melanoma: pathogenesis and trends in diagnosis and therapy. Journal of Veterinary Internal Medicine 1999; 13: 163-174.
2. Bergman PJ. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clinical Cancer Research 2003; 9: 1284-1290.
3. Morini M. C-kit gene product (CD117) immunoreactivity in canine and feline paraffin sections. Journal of Histochemistry and Cytochemistry 2004; 52: 705-708.
4. Smalley KS, Sondak VK and Weber JS. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histology and Histopathology 2009; 24: 643-650.
5. Webster JD. The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia 2006; 8: 104-111.
6. Capdeville R. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Reviews Drug Discovery 2002; 1: 493-502.
7. Beadling C. KIT gene mutations and copy number in melanoma subtypes. Clinical Cancer Research 2008; 14: 6821-6828.
8. Torres-Cabala CA. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Modern Pathology 2009; 22: 1446-1456.
9. Woodman SE. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Molecular Cancer Therapeutics 2009; 8: 2079-2085.
10. Isotani M. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs. Journal of Veterinary Internal Medicine 2008; 22: 985-988.
11. Rubin BP, Heinrich MC and Corless CL. Gastrointestinal stromal tumour. Lancet 2007; 369: 1731-1741.
12. Heinrich MC. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Journal of Clinical Oncology 2003; 21: 4342-4349.
13. Goldschmidt MH, Dunstan RW, Stannard AA, Von Tscharner C, Walder EJ and Yager JA. Histological Classification of Epithelial and Melanocytic Tumors of the Skin of Domestic Animals, Second Series. WHO International Histological Classification Tumors of Domestic Animals, Vol. 3, AFIP, Washington, DC 1998.
14. Jones CL. Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis. Journal of Veterinary Diagnostic Investigation 2004; 16: 95-100.
15. Zemke D, Yamini B and Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Veterinary Pathology 2002; 39: 529-535.
16. Sabattini S and Bettini G. An immunohistochemical analysis of canine haemangioma and haemangiosarcoma. Journal of Comparative Pathology 2009; 140: 158-168.
17. Yu CH. Comparative immunohistochemical characterization of canine seminomas and Sertoli cell tumors. Journal of Veterinary Science 2009; 10: 1-7.
18. Rivera RS. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Archiv 2008; 452: 27-32.
19. Montone KT. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression. Modern Pathology 1997; 10: 939-944.
20. Antonescu CR. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. International Journal of Cancer 2007; 121: 257-264.
21. Preziosi R, Morini M and Sarli G. Expression of the KIT protein (CD117) in primary cutaneous mast cell tumors of the dog. Journal of Veterinary Diagnostic Investigation 2004; 16: 554-561.
22. Webster JD. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Veterinary Pathology 2004; 41: 371-377.
23. Webster JD. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone. BMC Veterinary Research 2008; 4: 32.
24. Jilaveanu L. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clinical Cancer Research 2009; 15: 1076-1085.
25. Chute DJ, Cousar JB and Mills SE. Anorectal malignant melanoma: morphologic and immunohistochemical features. American Journal of Clinical Pathology 2006; 126: 93-100.
26. Potti A. Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. Journal of Cancer Research and Clinical Oncology 2004 130: 80-86.
27. Spangler WL and Kass PH. The histologic and Epidemiologic bases for prognostic considerations in canine melanocytic neoplasia. Veterinary pathology 2006; 43: 136-149.
28. Willmore-Payne C, Holden JA, Hirschowitz S and Layfield LJ. BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Human pathology 2006; 37: 520-527.
29. Willmore-Payne C, Holden JA, Tripp S and Layfield LJ. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Human pathology 2005; 36: 486-493.
30. Curtin JA, Busam K, Pinkel D and Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. Journal of clinical oncology 2006; 24: 4340-4346.